Your SlideShare is downloading. ×
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Pancreas Presentation
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Pancreas Presentation

2,542

Published on

1 Comment
0 Likes
Statistics
Notes
  • Is this an Energex Systems' or an Arbios Systems' concept? Or has Energex Systems merged with Arbios Systems?
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

No Downloads
Views
Total Views
2,542
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
81
Comments
1
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. The PancreAssist System
    A Bioartificial Pancreas
  • 2. Insulin-Glucose Relationship
    Normal vs. Diabetic
    Normal
    Glucose
    Insulin
    Diabetic
    Glucose
    Insulin Injection
    Insulin
    B
    L
    D
    S
  • 3. Diabetes
    Irregular blood glucose level control leads to complications; insulin injections are currently only practical therapy
    Insulin therapy fails to achieve consistent blood glucose; reliance on patient self-monitoring limits effectiveness
    PancreAssist™ System designed to provide automatic, continuous blood glucose level control
    Unmet Medical
    Need
    Shortcomings of
    Current Therapy
    ArbiosSolution
  • 4. PancreAssist SystemU.S. & Europe Market Potential
    No. of Patients Market Potential*
    100% of “Brittle” Diabetics 40,000 $ 200 million
    50% of All Type I Diabetics 700,000 $3,500 million
    10% of All Type II Diabetics 1,400,000 $7,000 million
    * Assume one device/reseeding per patient, per year at $5,000 each
  • 5. The PancreAssist System
    A Bioartificial Pancreas
    Objective
    To develop an implantable device
    containing pancreatic islets
    to improve blood glucose control
    in insulin-dependent diabetics
  • 6. Bioartificial Pancreas
    Device Types
    I
    I
    I
    Blood
    G
    G
    I
    Artery
    Vein
    I
    I
    Perfusion Device
    Pancreatic Islets
    Membrane
    G = Glucose I = Insulin
    G
    G
    I
    I
    I
    I
    G
    G
    Tissue
    Diffusion Device
  • 7. Insulin
    Pancreatic Islets
    Blood
    Blood
    Ultrafiltration Hollow Fiber
    Glucose
    in
    Antibodies
    out
    White Cells
    Insulin
    PancreAssist™ System
    Bioartificial Pancreas
    Semipermeable
    Membrane Coil
    Islet
    Seeding Ports
    Porcine Islets
    Device Housing
    PTFE
    Vascular Graft
    Device Schematic
  • 8. Reseedable PancreAssist™ System
  • 9. Key Advantages of Technology
    General
    • Biocompatible & Immunoprotective Membranes
    • 10. Non-transformed, Primary Cells
    • 11. Normal Cell Functions
    PancreAssist™ System
    • Direct Blood Contact for Optimum Oxygen Supply
    • 12. Rapid Insulin Release
    • 13. Physiological Blood Glucose Feedback
    • 14. No Anticoagulation or Immunosuppression
  • Experimental Protocol
    Total Pancreatectomy
    Islet Isolation
    (10-20 kg dog)
    Seeding of
    Seeding of
    2-3 weeks
    in vivo Device
    in vitro Device
    Device
    Continuous
    Implantation
    Perfusion
    Control of Hyperglycemia
    Insulin Output
  • 15. ARTIFICIAL PANCREASCanine Islets in Diabetic Dog
    Pancreatectomy
    Device Implanted
    Single Gen. 8 / PS-10
  • 16. ARTIFICIAL PANCREAS DEVICECanine Islets in Diabetic DogTwo Devices Implanted
    Pancreatectomy
    Devices
    Devices
    Implanted
    Removed
    PS-56
  • 17. Device Implanted
    Device Explanted
    PancreAssist System
    Xenogeneic Bioartificial Pancreas
    Porcine Islets in Diabetic Dog
  • 18.
  • 19. PancreAssist System
    Pre-clinical Studies
    Device Patency
    • Implanted 11 device designs in over 250 animals
    • 20. Achieved device patency for up to 4 years in large
    animal model without anticoagulation
    • Patency rate comparable to same size grafts in
    humans
    Cells
    • Porcine islet process established
  • PancreAssist System
    Pre-clinical Studies
    Device Function
    • Improved blood glucose control
    • 21. Reduced need by up to 75% for exogenous insulin
    for nine months in diabetic dogs
    • No immunosuppression required
    Summary
    • Because no immunosuppression is required,
    the BAP may be used prior to the development
    of diabetic complications
  • 22. PancreAssist SystemDevelopment Plan
    • Establish joint development collaborations to share risk and expand capability in:
    - Pancreatic beta cell line development
    - Implantable device technology
    - Medical device marketing & sales

×